Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in Washington: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 25 | 1,606 | 37% |
| 2020 | 22 | 1,441 | 40% |
| 2021 | 24 | 1,430 | 43% |
| 2022 | 27 | 1,466 | 46% |
| 2023 | 32 | 1,697 | 50% |
| 2024 | 31 | 1,779 | 54% |
| 2025 from claims | – | 1,989 1,825–2,104 | 54% |
| 2026 forecast | – | 2,114 1,860–2,439 | 54% |
| 2027 forecast | – | 2,221 1,899–2,647 | 55% |
| 2028 forecast | – | 2,332 1,946–2,856 | 56% |
| 2029 forecast | – | 2,449 2,000–3,071 | 57% |
| 2030 forecast | – | 2,570 2,059–3,294 | 57% |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 61% of the cases CMS names in Washington; 17 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 13% inpatient hospital, 87% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~2,100 | ~260 | ~1,900 |
| 2027 · ~2,200 | ~260 | ~2,000 |
| 2028 · ~2,300 | ~260 | ~2,100 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 11% (13% in 2025), hospital outpatient about 89% (87% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 119 | 8,499+11%/yr | +11%/yr | 2.6 | 2% | 16,800 in 2030+12%/yr |
| Arizona | 38 | 3,079+16%/yr | +16%/yr | 4.2 | 0% | 5,590 in 2030+10%/yr |
| Colorado | 18 | 1,328+5.9%/yr | +5.9%/yr | 2.8 | 0% | 2,020 in 2030+7.2%/yr |
| Oregon | 10 | 796+5.6%/yr | +5.6%/yr | 1.9 | 0% | 1,500 in 2030+11%/yr |
| Nevada | 11 | 545+13%/yr | +13%/yr | 1.9 | 0% | 870 in 2030+8.2%/yr |
| Utah | 6 | 444+15%/yr | +15%/yr | 2.1 | 0% | 960 in 2030+14%/yr |
| Idaho | 5 | 286+3%/yr | +3%/yr | 1.4 | 0% | 650 in 2030+15%/yr |
| Montana | 5 | 277+1.2%/yr | +1.2%/yr | 1.5 | 0% | 310 in 2030+1.7%/yr |
| Hawaii | 6 | 241+24%/yr | +24%/yr | 1.9 | 0% | 590 in 2030+16%/yr |
| New Mexico | 4 | 210+8.1%/yr | +8.1%/yr | 0.9 | 0% | 570 in 2030+18%/yr |
| Alaska | 2 | 179+25%/yr | +25%/yr | 1.5 | 0% | 660 in 2030+24%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 393 | 77,215−3.7%/yr | −3.7%/yr | 104.51.0× | 45% | 78,700 in 2030+0.3%/yr |
| ERCP & endoscopic ultrasound | 46 | 2,920−2.5%/yr | −2.5%/yr | 3.91.1× | 0% | 3,710 in 2030+4.1%/yr |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in Washington · Every state · Compare with California
Verathon leads with 32% of company spending on these surgeons in 2025, +25 pts on 2024.
In 2025, 18 companies reported engagement with Washington’s surgeons worth $41K in consulting, speaking, meals and travel tied to these products, about $1,339 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.